Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 7/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630971 | 0.92 | HCAR3 (0.50) | DGAT1HCAR3KDM4EALDH1A1USP30 | |
| SCHEMBL20894366 | 0.92 | HCAR3 (0.50) | DGAT1HCAR3KDM4EALDH1A1USP30 | |
| SCHEMBL29742737 | 0.84 | DGAT1 (0.42) | DGAT1HCAR3USP30LPLLIPG | |
| SCHEMBL29742741 | 0.82 | DGAT1 (0.40) | DGAT1KDM4EUSP30LPLLIPG | |
| SCHEMBL19996746 | 0.81 | DGAT1 (0.43) | DGAT1USP30LPLLIPGCA1 | |
| SCHEMBL22674352 | 0.81 | DGAT1 (0.43) | DGAT1USP30LPLLIPGCA1 | |
| SCHEMBL182973 | 0.81 | DGAT1 (0.46) | DGAT1HCAR3KDM4EALDH1A1USP30 | |
| SCHEMBL21327400 | 0.80 | DGAT1 (0.57) | DGAT1USP30LPLLIPGCA1 | |
| SCHEMBL2432651 | 0.79 | LPL (0.50) | DGAT1HCAR3LPLLIPGCA1 | |
| SCHEMBL25066062 | 0.79 | DGAT1 (0.46) | DGAT1HCAR3USP30LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010121164-A2 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | HTR4, HTR1A, HTR3B | DGAT1 3980/4885HCAR3 1838/4885KDM4E 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.